Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works

The Somatic Genomic Landscape of Glioblastoma

Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

THE TOXICITY OF POISONS APPLIED JOINTLY1

BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works

ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays

Hu, Y., & Smyth, G. K. (2009) · Journal of Immunological Methods · doi:10.1016/j.jim.2009.06.008 · Cited by 2,091 · see citing works

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

Weller, M., van den Bent, M. J., Tonn, J. C., Stupp, R., Preusser, M., Moyal, E. C., Henriksson, R., Rhun, É. L., Balañá, C., Chinot, O. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,094 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · see citing works

MGMT testing—the challenges for biomarker-based glioma treatment

Wick, W., Weller, M., van den Bent, M. J., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M. E., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 580 · see citing works

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works

Insulin-like growth factors and cancer

Fürstenberger, G., & Senn, H.-J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00731-3 · Cited by 538 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

Targeting the MDM2-p53 Interaction for Cancer Therapy

Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 364 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells

Coll-Mulet, L., Iglesias‐Serret, D., Santidrián, A. F., Cosialls, A. M., de Frías, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3273 · Cited by 233 · see citing works

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131 · see citing works

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme

Villalonga-Planells, R., Coll-Mulet, L., Martínez‐Soler, F., Castaño, E., Acebes, J.-J., Gimenez‐Bonafé, P., Gil, J., & Tortosa, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018588 · Cited by 128 · see citing works

Causal Mechanistic Regulatory Network for Glioblastoma Deciphered Using Systems Genetics Network Analysis

Plaisier, C. L., O’Brien, S. A., Bernard, B. M., Reynolds, S. M., Simon, Z., Toledo, C. M., Ding, Y., Reiss, D. J., Paddison, P. J., & Baliga, N. S. (2016) · Cell Systems · doi:10.1016/j.cels.2016.06.006 · Cited by 116 · see citing works

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells

Vilgelm, A. E., Pawlikowski, J. S., Liu, Y., Hawkins, O. E., Davis, T. A., Smith, J., Weller, K. P., Horton, L. W., McClain, C. M., Ayers, G. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2405 · Cited by 115 · see citing works

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas

Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114 · see citing works

Impaired Hepatocyte DNA Synthetic Response Posthepatectomy in Insulin-Like Growth Factor Binding Protein 1-Deficient Mice with Defects in C/EBPβ and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Regulation

Leu, J. I.-J., Crissey, M. A. S., Craig, L. E., & Taub, R. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1251-1259.2003 · Cited by 108 · see citing works

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Cesne, A. L., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., Jonge, M. J. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 99 · see citing works

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Saddler, C. M., Ouillette, P. D., Kujawski, L. A., Shangary, S. K., Talpaz, M., Kaminski, M. S., Erba, H. P., Shedden, K., Wang, S., & Malek, S. N. (2007) · Blood · doi:10.1182/blood-2007-09-112698 · Cited by 96 · see citing works

Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2

Wick, W., Grimmel, C., Wild‐Bode, C., Platten, M., Arpin, M., & Weller, M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-10-03360.2001 · Cited by 90 · see citing works

The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma

Lakoma, A., Barbieri, E., Agarwal, S., Jackson, J. R., Chen, Z., Kim, Y., McVay, M. C., Shohet, J. M., & Kim, E. S. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.26 · Cited by 77 · see citing works

Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)

Yee, K. W. L., Martinelli, G., Vey, N., Dickinson, M. J., Seiter, K. P., Assouline, S. E., Drummond, M. W., Yoon, S., Kasner, M. T., Lee, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.116.116 · Cited by 76 · see citing works

Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf ^−/− mouse model

Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64 · see citing works

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway

Silginer, M., Burghardt, I., Gramatzki, D., Bunse, L., Leske, H., Rushing, E. J., Hao, N., Platten, M., Weller, M., & Roth, P. (2015) · Oncogene · doi:10.1038/onc.2015.387 · Cited by 60 · see citing works

Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?

Lemke, D., Weiler, M., Blaes, J., Wiestler, B., Jestaedt, L., Klein, A., Löw, S., Eisele, G., Radlwimmer, B., Capper, D., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12802 · Cited by 57 · see citing works

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma

Keßler, T., Sahm, F., Blaes, J., Osswald, M., Rübmann, P., Milford, D., Urban, S., Jestaedt, L., Heiland, S., Bendszus, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2910 · Cited by 55 · see citing works

Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia <i>In Vitro</i> and <i>In Vivo</i>

Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52 · see citing works

Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10

Hertenstein, A., Schumacher, T., Litzenburger, U. M., Opitz, C. A., Falk, C. S., Serafini, T. A., Wick, W., & Platten, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.013 · Cited by 37 · see citing works

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Hata, A. N., Rowley, S. C., Archibald, H. L., Gomez‐Caraballo, M., Siddiqui, F. M., Ji, F., Jung, J., Light, M. E., Lee, J. S., Debüssche, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.258 · Cited by 34 · see citing works

Therapeutic Efficacy of <i>p53</i> Restoration in <i>Mdm2</i> -Overexpressing Tumors

Li, Q., Zhang, Y., El-Naggar, A. K., Xiong, S., Yang, P., Jackson, J. G., Chau, G., & Lozano, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0089 · Cited by 30 · see citing works

Phase 1 summary of plasma concentration–QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML

Blotner, S. D., Chen, L.-C., Ferlini, C., & Zhi, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3534-7 · Cited by 16 · see citing works

High concentrations of pyridoxal stimulate the expression of IGFBP1 in HepG2 cells through upregulation of the ERK/c-Jun pathway

Zhang, P., Suidasari, S., Hasegawa, T., Yanaka, N., & Katô, N. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1629 · Cited by 13 · see citing works

Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N²M²).

Hertenstein, A., Jones, D., Sahm, F., Pfaff, E., Hutter, B., Karapanagiotou‐Schenkel, I., Eisenmenger, A., Osswald, M., Wick, A., Löw, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.tps2084 · Cited by 4 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

MDM2 inhibition: an important step forward in cancer therapy

Konopleva, M. Y., Martinelli, G., Daver, N. G., Papayannidis, C., Wei, A. H., Higgins, B., Ott, M., Mascarenhas, J. O., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376 · see citing works

Targeting p53 for the treatment of cancer

Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 351 · see citing works

Glioblastoma Therapy: Past, Present and Future

Obrador, E., Moreno-Murciano, P., Oriol‐Caballo, M., López‐Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Bonet, L. G. G., Martínez‐Cadenas, C., Estrela, J. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 263 · see citing works

Towards the overcoming of anticancer drug resistance mediated by p53 mutations

Cao, X., Hou, J., An, Q., Assaraf, Y. G., & Wang, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100671 · Cited by 176 · see citing works

Targeting strategies for bone diseases: signaling pathways and clinical studies

Xu, H., Wang, W., Liu, X., Huang, W. H., Chen, Z., Xu, Y., Yang, H., Bai, J., & Geng, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01467-8 · Cited by 173 · see citing works

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 147 · see citing works

Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression

Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02586-w · Cited by 111 · see citing works

In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma

Soni, V., Adhikari, M., Simonyan, H., Lin, L., Sherman, J. H., Young, C. N., & Keidar, M. (2021) · Cancers · doi:10.3390/cancers13174485 · Cited by 66 · see citing works

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?

Hároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 71 · see citing works

STAT3 and p53: Dual Target for Cancer Therapy

Pham, T., Park, H., Kim, J., Hong, J. T., & Yoon, D. (2020) · Biomedicines · doi:10.3390/biomedicines8120637 · Cited by 61 · see citing works

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma

Traweek, R. S., Cope, B. M., Roland, C. L., Keung, E. Z.-Y., Nassif, E. F., & Erstad, D. J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1006959 · Cited by 61 · see citing works

Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application

Ren, X., Huang, M., Weng, W., Xie, Y., Wu, Y., Zhu, S., Zhang, Y., Li, D., Lai, J., Shen, S., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101277 · Cited by 55 · see citing works

IGFBP-1 in cancer: expression, molecular mechanisms, and potential clinical implications.

Lin, Y.-W., Weng, X., Huang, B.-L., Guo, H., Xu, Y., & Peng, Y. (2021) · PubMed Central · Cited by 45 · see citing works

The intricate interplay between HIFs, ROS, and the ubiquitin system in the tumor hypoxic microenvironment

Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 44 · see citing works

Glioblastoma precision therapy: From the bench to the clinic

Yuan, Z., Wu, W., Bi, H., Yang, D., & Zhang, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.027 · Cited by 43 · see citing works

MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy

Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40 · see citing works

Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling

Chen, W., Yang, K., Zhang, Y.-Z., Lin, Z.-S., Chen, J.-W., Qi, S.-F., Wu, C., Feng, G., Yang, D.-J., Chen, M., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03168-8 · Cited by 41 · see citing works

Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells

Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 40 · see citing works

Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

Alaseem, A. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101790 · Cited by 36 · see citing works

Xanthohumol suppresses glioblastoma via modulation of Hexokinase 2 -mediated glycolysis

Yuan, J., Peng, G., Xiao, G., Yang, Z., Huang, J., Liu, Q., Yang, Z., & Liu, D. (2020) · Journal of Cancer · doi:10.7150/jca.33045 · Cited by 33 · see citing works

Role of Tumor and Stroma-Derived IGF/IGFBPs in Pancreatic Cancer

Thomas, D., & Radhakrishnan, P. (2020) · Cancers · doi:10.3390/cancers12051228 · Cited by 31 · see citing works

MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation

Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30 · see citing works

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma

Ntafoulis, I., Koolen, S. L. W., Leenstra, S., & Lamfers, M. L. M. (2022) · Cancers · doi:10.3390/cancers14153705 · Cited by 31 · see citing works

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed

Zanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 29 · see citing works

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)

Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 27 · see citing works

Integrated analysis identified core signal pathways and hypoxic characteristics of human glioblastoma

Gao, Y., Zhang, E., Liu, B., Zhou, K., He, S., Feng, L., Wu, G., Cao, M., Wu, H., Cui, Y., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14507 · Cited by 21 · see citing works

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma

Keßler, T., Berberich, A., Casalini, B., Drüschler, K., Ostermann, H., Dormann, A., Walter, S., Hai, L., Schlesner, M., Herold‐Mende, C. C., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz060 · Cited by 21 · see citing works

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01270-y · Cited by 21 · see citing works

MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas

Song, Y., Zhang, L., Jiang, Y., Hu, T., Zhang, D., Qiao, Q., Wang, R., Wang, M., & Han, S. (2019) · Theranostics · doi:10.7150/thno.35747 · Cited by 21 · see citing works

Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer

Luo, H., Si, D., Sun, X.-J., Wang, M., Yang, Y.-B., Wang, B., Wen, H., Li, W., & Li, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115282 · Cited by 17 · see citing works

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors

Alimova, I. N., Wang, D., Danis, E. P., Pierce, A. M., Donson, A. M., Serkova, N. J., Madhavan, K. P. C., Lakshmanachetty, S., Balakrishnan, I., Foreman, N. K., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5322 · Cited by 16 · see citing works

cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma

Berberich, A., Schmitt, L.-M., Pusch, S., Hielscher, T., Rübmann, P., Hucke, N., Latzer, P., Heßling, B., Lemke, D., Keßler, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03348-z · Cited by 16 · see citing works

Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin

Sani, S., Pallaoro, N., Messé, M., Bernhard, C., Étienne-Selloum, N., Kessler, H., Marinelli, L., Entz‐Werlé, N., Foppolo, S., Martin, S., et al. (2022) · Cancers · doi:10.3390/cancers14020369 · Cited by 12 · see citing works

Novel Therapeutics and drug-delivery Approaches in the Modulation of Glioblastoma Stem Cell Resistance

Smiley, S. B., Zarrinmayeh, H., DAS, S. K., Pollok, K. E., Vannier, M. W., & Veronesi, M. C. (2022) · Therapeutic Delivery · doi:10.4155/tde-2021-0086 · Cited by 11 · see citing works

In Vitro/In Vivo Translation of Synergistic Combination of MDM2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I

Witkowski, J., Polak, S., Rogulski, Z., & Pawelec, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112984 · Cited by 9 · see citing works

Effects of natural 24-epibrassinolide on inducing apoptosis and restricting metabolism in hepatocarcinoma cells

Zhou, H., Zhuang, W., Huang, H., Ma, N., Lei, J., Jin, G., Wu, S., Zhou, S., Zhao, X., Lan, L., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154428 · Cited by 9 · see citing works

Association of M2 macrophages with EMT in glioma identified through combination of multi-omics and machine learning

Feng, P., Liu, S., Yuan, G., & Pan, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34119 · Cited by 9 · see citing works

miR-16-5p enhances sensitivity to RG7388 through targeting PPM1D expression (WIP1) in Childhood Acute Lymphoblastic Leukemia

Zanjirband, M., Rahgozar, S., & Aberuyi, N. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.113 · Cited by 9 · see citing works

New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics

Grigoreva, T. A., Sagaidak, A. V., Novikova, D., & Tribulovich, V. G. (2024) · Biomedicines · doi:10.3390/biomedicines12030547 · Cited by 9 · see citing works

Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations

Pairawan, S. S., Akçakanat, A., Kopetz, S., Tapia, C., Zheng, X., Chen, H., Ha, M. J., Rizvi, Y. Q., Holla, V. R., Wang, J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05193-z · Cited by 10 · see citing works

Integrative machine learning and bioinformatics analysis unveil key genes for precise glioma classification and prognosis evaluation

Yang, P., Feng, P., Tian, G., Zhao, G., Yuan, G., & Pan, Y. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108510 · Cited by 8 · see citing works

The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article

Azab, M. A. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040018 · Cited by 8 · see citing works

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Pervushin, N. V., Nilov, D. K., Pushkarev, S. V., Shipunova, V. O., Станиславовна, Б. А., Yapryntseva, M. A., Kopytova, D. V., Zhivotovsky, B., & Kopeina, G. S. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02014-8 · Cited by 6 · see citing works

Comprehensive analysis of senescence-related genes identifies prognostic clusters with distinct characteristics in glioma

Wei, W., Dang, Y., Chen, G., Han, C., Zhang, S., Zhu, Z., Bie, X., & Xue, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-93482-8 · Cited by 6 · see citing works

Recent insight into the role of RING-finger E3 ligases in glioma

Cao, Y., Zhou, H., Chen, X., Li, Y., Hu, J., Zhou, G., & Wang, L. (2021) · Biochemical Society Transactions · doi:10.1042/bst20201060 · Cited by 6 · see citing works

Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53

Taritsa, I. C., & Fossel, E. T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529483 · Cited by 5 · see citing works

Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma

Jiang, X., Zhang, W., Li, L., & Xie, S. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609985 · Cited by 5 · see citing works

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0244 · Cited by 2 · see citing works

Machine learning unravels the mysteries of glioma typing and treatment

Dang, Y., Chen, Y., Chen, J., Yuan, G., & Pan, Y. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.101969 · Cited by 1 · see citing works

Exploiting Synthetic Lethality of PRMT5 for Precision Treatment of MTAP-Deficient Glioblastoma

Nguyen, T. T. T., Yi, E. S., & Badr, C. E. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5030027 · Cited by 1 · see citing works

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors

Refaat, A., Cho, H. P., Williams, J. S., Stripay, J. L., Blankenship, K., Mercer, K., DeVries, R., Connelly, M., Ganguly, D., Robinson, S., et al. (2025) · Neuro-Oncology Pediatrics · doi:10.1093/neuped/wuaf018 · Cited by 1 · see citing works

Synthesis and Biological Evaluation of a Novel Dual-Targeting Small Molecule Drug Conjugate Modulating the Crosstalk between α5β1 Integrin and MDM2 in Glioblastoma

Arrigoni, F., Ferrari, A., Prpić, H., Markevičiūtė, E., Muzi, A., Roscilli, G., Gazzola, S., & Piarulli, U. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00669 · Cited by 1 · see citing works

Research Progress on Small Molecule Inhibitors of MDM2-p53 Protein-protein Interaction

Hu, M. Y., Xu, C., Xu, M., He, S., & Liu, D. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206358340250121060830 · Cited by 1 · see citing works

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259

Investigational new drugs against glioblastoma

Kamson, D. O., Khela, H. S., & Laterra, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00002-6

Targeting the p53 pathway to treat Malignant Rhabdoid and Atypical Teratoid Rhabdoid TumorsPreprint

Roussel, M. F., Cho, H., Stripay, J. L., Refaat, A., Blankenship, K., Williams, J. S., Mercer, K., Connelly, M., Ganguly, D., Robinson, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2094243/v1

Additional file 2 of Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression

Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606688

A comprehensive analysis of transcription factors identified TCF3 as a prognostic target for glioma

Li, Q., Feng, P., Liu, S., Tian, G., Yuan, G., & Pan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-09924-w

Additional file 5 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928348

Additional file 3 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928339

Additional file 1 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928333

Additional file 4 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928342

Additional file 6 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928351

Additional file 2 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928336

Additional file 7 of TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist

Xu, C., Liu, H., Pirozzi, C. J., Chen, L. H., Greer, P. K., Diplas, B. H., Zhang, L., Waitkus, M. S., He, Y., & Yan, H. (2021) · Figshare · doi:10.6084/m9.figshare.16928354

Additional file 1 of Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling

Chen, W., Yang, K., Zhang, Y.-Z., Lin, Z.-S., Chen, J.-W., Qi, S.-F., Wu, C.-F., Feng, G.-K., Yang, D.-J., Chen, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26944368

Additional file 1 of Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression

Deng, M., Zhang, L., Zheng, W., Chen, J., Du, N., Li, M., Chen, W., Huang, Y., Zeng, N., Song, Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606685

Glioblastoma resistance to temozolomide : implication of α5β1 integrin and p53 signalling pathways

Sani, S. (2020) · theses.fr (ABES) · doi:10.70675/9566c585z0508z455bz9064z6bb61435b210

Hétérogénéité et plasticité de l’intégrine α5 dans les cellules souches de glioblastome

Messé, M. (2023) · theses.fr (ABES) · doi:10.70675/5bee424dz19e3z4870zb9b1z927eaa272304

The p53/Mdm2 Pathway in Hepatocellular Carcinoma: From Molecular Pathogenesis to Targeted Therapies

Kirkness, K., & Mann, D. A. (2026) · Livers · doi:10.3390/livers6030039

Trametinib-mediated MEK inhibition impairs cancer cell viability and invasion in patient-derived tumor avatars of glioblastoma with extraneural metastases: A proof-of-concept study

Novak, M., Majc, B., Vidmar, M. S., Kladnik, Š., Milavec, T. K., Habič, A., Galun, S. K., Žižek, P., Porčnik, A., Matjašič, A., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119832

Hormonal signaling in glioblastoma: emerging roles in stemness and tumor plasticity

Jessica, G.-S., Cañas‐Linares, A., & García‐López, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1924678

Strategies for Overcoming Acquired Resistance of Tumor Cells to MDM2 Inhibitors

Pervushin, N. V., Просандеева, Е. С., Zhivotovsky, B., & Kopeina, G. S. (2026) · Biochemistry (Moscow) · doi:10.1134/s0006297926601875

BindingDB Entry 50020150: Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.

BindingDB (2024) · UC San Diego · doi:10.7270/q27s7t60

Abstract 6276: Brain penetrant MDM2 inhibitor RG7388 extends survival benefit of radiation treatment in select glioblastoma patient-derived xenograft models

Gupta, S. K., Mladek, A. C., Telele, S., Mohammad, A. S., He, L., Hu, Z., Bakken, K. K., Burgenske, D. M., Carlson, B. L., Elmquist, W. F., et al. (2020) · Cancer Research · doi:10.1158/1538-7445.am2020-6276 · Cited by 1 · see citing works

RTID-05. SURGICAL WINDOW OF OPPORTUNITY TRIAL REVEALS MECHANISMS OF RESPONSE AND RESISTANCE TO NAVTEMADLIN (KRT-232) IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Rendo, V., Lee, E. Q., Bossi, C. C., Khuu, N., Pal, S., Reynolds, A. R. N., Fassinou, A. C. R., Ligon, K. L., Beroukhim, R., Wen, P. Y., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad179.0996

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis

Satō, A., Sunayama, J., Matsuda, K., Seino, S., Suzuki, K., Watanabe, E., Tachibana, K., Tomiyama, A., Kayama, T., & Kitanaka, C. (2011) · Stem Cells · doi:10.1002/stem.753 · Cited by 125 · see citing works

Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1

Corrales-Guerrero, S., Cui, T., Castro-Aceituno, V., Yang, L., Nair, S., Feng, H., Venere, M., Yoon, S. M., DeWees, T. A., Shen, C., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216308 · Cited by 24 · see citing works

EXTH-19. OPTIMIZING MDM2 INHIBITION FOR THE TREATMENT OF GLIOBLASTOMA

Rendo, V., Lee, E. Q., Khuu, N., Pelton, K., Lapinskas, E., Wen, P. Y., Ligon, K. L., & Beroukhim, R. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac209.818